Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy - TNXP News | RalliesTonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy
T
TNXP• Investor deck highlights TONMYA launch traction and pipeline plans
- Tonix highlighted early commercial traction for fibromyalgia drug TONMYA, showing 1Q’26 net sales of USD 3.7 million.
- Launch-to-date net sales totaled USD 5.1 million through March 31, 2026; more than 2,600 unique prescribers wrote prescriptions.
- Cash and cash equivalents were about USD 185.5 million as of March 31, 2026; no debt; runway expected into early Q2’27.
- Pipeline focus included TNX-4800 Lyme prevention program with an adaptive Phase 2 field study planned for 1H’27, pending FDA agreement.
- Other planned studies cited TNX-1500 in organ transplant rejection in 2H’26, TNX-2900 in Prader-Willi syndrome in 1Q’27.
•
